Log in

Relevant bibliographies by topics / Transplant Immunobiology / Journal articles

To see the other types of publications on this topic, follow the link: Transplant Immunobiology.

Journal articles on the topic 'Transplant Immunobiology'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Transplant Immunobiology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dantal, Jacques, Regis Josien, and Jean Paul Soulillou. "Advances in transplant immunobiology." Current Opinion in Nephrology and Hypertension 10, no. 3 (2001): 349–54. http://dx.doi.org/10.1097/00041552-200105000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shoskes, Daniel A., and Hetal Patel. "Update on transplant immunobiology." Current Opinion in Urology 6, no. 2 (1996): 93–99. http://dx.doi.org/10.1097/00042307-199603000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hancock, Wayne W. "Chemokines and Transplant Immunobiology." Journal of the American Society of Nephrology 13, no. 3 (2002): 821–24. http://dx.doi.org/10.1681/asn.v133821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Morris, Peter J. "The Immunobiology of Cell Transplantation." Cell Transplantation 2, no. 1 (1993): 7–12. http://dx.doi.org/10.1177/096368979300200104.

Full text

Abstract:

The potential for cell transplantation is enormous, not only in replacement therapy in conditions such as diabetes but also in approaches to gene therapy and the induction of tolerance to organ transplants. Immunobiological aspects of cell transplantation include: 1) isolation and purification of cells for transplantation, 2) preservation of cells, 3) technical problems of transplantation, 4) the immune response to cell transplants, 5) prevention of the immune response to cell allografts, 6) delivery and regulation of the product of the cell transplant, 7) xenotransplantation, 8) gene therapy.

APA, Harvard, Vancouver, ISO, and other styles

5

Stadlbauer, Thomas H. W., and Jerzy W. Kupiec–Weglinski. "Immunobiology of Sensitization in Transplant Recipients." American Journal of the Medical Sciences 313, no. 5 (1997): 268–74. http://dx.doi.org/10.1016/s0002-9629(15)40115-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Paul, Leendert C. "Immunobiology of Chronic Renal Transplant Rejection." Blood Purification 13, no. 3-4 (1995): 206–18. http://dx.doi.org/10.1159/000170203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schaenman, Joanna, and Deena Goldwater. "The aging transplant population and immunobiology." Current Opinion in Organ Transplantation 25, no. 3 (2020): 255–60. http://dx.doi.org/10.1097/mot.0000000000000760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stadlbauer, Thomas H. W., and Jerzy W. Kupiec-Weglinski. "Immunobiology of Sensitization in Transplant Recipients." American Journal of the Medical Sciences 313, no. 5 (1997): 268–74. http://dx.doi.org/10.1097/00000441-199705000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ali, Simi, Lynne A. Hardy, and John A. Kirby. "Transplant immunobiology: a crucial role for heparan sulfate glycosaminoglycans?" Transplantation 75, no. 11 (2003): 1773–82. http://dx.doi.org/10.1097/01.tp.0000065805.97974.93.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Barry, C. T., S. Cao, H. Monge, S. K. So, C. O. Esquivel, and P. O. Brown. "TOWARDS A GENOMIC ANALYSIS OF TRANSPLANT IMMUNOBIOLOGY AND RELATED PHENOMENA." Transplantation 65, Supplement (1998): 111. http://dx.doi.org/10.1097/00007890-199805131-00131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Barry, C. T., S. Cao, H. Monge, S. K. So, C. O. Esquivel, and P. O. Brown. "TOWARDS A GENOMIC ANALYSIS OF TRANSPLANT IMMUNOBIOLOGY AND RELATED PHENOMENA." Transplantation 65, no. 12 (1998): S35. http://dx.doi.org/10.1097/00007890-199806270-00150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Morales-Tirado, Vanessa, Wioleta Luszczek, Marié van der Merwe, and Asha Pillai. "Regulatory Immunotherapy in Bone Marrow Transplantation." Scientific World JOURNAL 11 (2011): 2620–34. http://dx.doi.org/10.1100/2011/768948.

Full text

Abstract:

Every year individuals receive hematopoietic stem cell transplantation (HSCT) to eradicate malignant and nonmalignant disease. The immunobiology of allotransplantation is an area of ongoing discovery, from the recipient's conditioning treatment prior to the transplant to the donor cell populations responsible for engraftment, graft-versus-host disease, and graft-versus-tumor effect. In this review, we focus on donor-type immunoregulatory T cells, namely, natural killer T cells (NKT) and regulatory T cells (Treg), and their current and potential roles in tolerance induction after allogeneic HSC

APA, Harvard, Vancouver, ISO, and other styles

13

Maluf, DG, RA Fisher, R. Riley, et al. "Immunobiology and long-term graft function in a transplant heterotopic renal rat model." Clinical Transplantation 16, s7 (2002): 6–14. http://dx.doi.org/10.1034/j.1399-0012.16.s7.1.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "IMMUNOBIOLOGY OF POST-TRANSPLANT SKIN CANCER: DO CD4+ NKT CELLS HAVE A REGULATORY ROLE?" Transplantation 82, Suppl 2 (2006): 870. http://dx.doi.org/10.1097/00007890-200607152-02428.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Scherer, Lauren, Amanda Bell Grimes, Taylor Kim, and Caridad A. Martinez. "Refractory Autoimmune Hemolytic Anemia Following Hematopoietic Stem Cell Transplant (HSCT) in the Setting of Impaired Immune Reconstitution Among Pediatric HSCT Recipients." Blood 132, Supplement 1 (2018): 4580. http://dx.doi.org/10.1182/blood-2018-99-120277.

Full text

Abstract:

Abstract Background: Autoimmune hemolytic anemia is a well-recognized complication of hematopoietic stem cell transplant (HSCT). While occurring in only ~2-6% of pediatric patients receiving HSCT, it is associated with significant morbidity and mortality of up to 50%. Post-transplant AIHA is poorly studied due to small patient numbers. Therefore, risk factors for the development of post-transplant AIHA are not well delineated and optimal treatment strategies are not known. Disease course is often refractory and multiply relapsing, with current treatment approaches remaining empiric. The most c

APA, Harvard, Vancouver, ISO, and other styles

16

Velardi, Andrea, Loredana Ruggeri, Dimitris Ziagkos, et al. "Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT." Blood 128, no. 22 (2016): 3472. http://dx.doi.org/10.1182/blood.v128.22.3472.3472.

Full text

Abstract:

Abstract Introduction Trans-placental trafficking of maternal and fetal cells during pregnancy establishes long-term, reciprocal micro-chimerism in both mother and child (Maloney et al., J Clin Invest, 104:41, 1999). As a consequence, the immune system of the mother may become sensitized to paternal histocompatibility antigens. In fact, antibodies directed against paternal HLA-antigens (van Rood JJ et al., Nature 181:1735, 1958) and T lymphocytes directed against paternal major and minor histocompatibility antigens (van Kampen CA et al., Hum Immunol 62:201, 2001; Verdijk RM et al., Blood 103:1

APA, Harvard, Vancouver, ISO, and other styles

17

Nishio-Lucar, Angie, Rasheed A. Balogun, and Scott Sanoff. "Therapeutic apheresis in kidney transplantation: A review of renal transplant immunobiology and current interventions with apheresis medicine." Journal of Clinical Apheresis 28, no. 1 (2013): 56–63. http://dx.doi.org/10.1002/jca.21268.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Meier, D., H. Cagnola, D. Ramisch, et al. "Analysis of immune cells draining from the abdominal cavity as a novel tool to study intestinal transplant immunobiology." Clinical & Experimental Immunology 162, no. 1 (2010): 138–45. http://dx.doi.org/10.1111/j.1365-2249.2010.04192.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Greco, Raffaella, Fabio Ciceri, Maddalena Noviello, et al. "How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party." Blood 128, no. 22 (2016): 4581. http://dx.doi.org/10.1182/blood.v128.22.4581.4581.

Full text

Abstract:

Abstract Background: Post transplant immune reconstitution plays a major role in determining the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is currently monitored with different techniques in different Centers, with the aim of identifying clinically relevant immunological biomarkers. However, it is unclear which and how many of these immunological tests are currently performed on a routine basis, and which ones have the potential to predict patient outcome, and possibly guide patient care after allo-HSCT. Methods: The EBMT Cellular Therapy & Immunobiolog

APA, Harvard, Vancouver, ISO, and other styles

20

Bondanza, Attilio, Loredana Ruggeri, Dimitris Ziagkos, et al. "An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT." Blood 126, no. 23 (2015): 1929. http://dx.doi.org/10.1182/blood.v126.23.1929.1929.

Full text

Abstract:

Abstract Introduction and Aim: HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute myeloid (AML) or lymphoid leukemia (ALL). Unfortunately, graft manipulation employed to overcome the HLA barrier significantly delays immune reconstitution, posing the patients at risk of infections. Accordingly, non-relapse mortality after haplo-HSCT clearly extends beyond day 100 post-transplant. Over the years, different approaches have been investigated to speed-up immune reconstitution. In the absence of validated immune biomarkers

APA, Harvard, Vancouver, ISO, and other styles

21

Garfin, Phillip M., Patrick Viatour, Dullei Min, et al. "RB Controls Size, Cellularity, and T Cell Output of the Mouse Thymus." Blood 120, no. 21 (2012): 835. http://dx.doi.org/10.1182/blood.v120.21.835.835.

Full text

Abstract:

Abstract Abstract 835 The establishment of the thymic microenvironment early in life is crucial for the production functional T cells. Conversely, thymic involution results in a decreased T cell output. Thymic involution has important health implications especially following bone marrow transplant. Our objective is to determine molecular and cellular mechanisms that will allow for regeneration of involuted thymic tissue, restore production of naïve T cells, and improve immune function while improving our understanding of immunobiology. In this pursuit, we have focused on the Retinoblastoma fa

APA, Harvard, Vancouver, ISO, and other styles

22

Paviglianiti, Annalisa, Erick Xavier, Patrice Ceballos, et al. "Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study." Blood 126, no. 23 (2015): 3203. http://dx.doi.org/10.1182/blood.v126.23.3203.3203.

Full text

Abstract:

Abstract Although outcomes for multiple myeloma (MM) have improved with the use of drugs such as bortezomib, thalidomide, lenalidomide and autologous stem cell transplantation (ASCT), it remains an incurable disease. Allogeneic stem cell transplantation (AlloSCT) is not a standard therapy for MM, but it potentially provides a graft versus myeloma effect. The use of reduced-intensity conditioning (RIC) and the autologous-allogeneic tandem transplantation have broadened the use of AlloSCT in patients (pts) with MM. Nevertheless, relapse incidence (RI) after AlloSCT remains high and investigation

APA, Harvard, Vancouver, ISO, and other styles

23

Sobecks, Ronald M., Meighan M. Gallagher, Medhat Askar, et al. "Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee." Blood 122, no. 21 (2013): 159. http://dx.doi.org/10.1182/blood.v122.21.159.159.

Full text

Abstract:

Abstract Disease relapse is a significant cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HCT). In the setting of reduced-intensity conditioning (RIC), a graft-versus-leukemia (GVL) effect is critical for successful outcomes in patients with advanced myeloid malignancies. A GVL effect has been attributed in part to donor-derived alloreactive natural killer (NK) cells, which are regulated by interaction of KIRs with their HLA-class I ligands. Several models of NK reactivity (missing KIR ligand, centromeric haplotype-B content, non-tolerized KIR2DS1) have bee

APA, Harvard, Vancouver, ISO, and other styles

24

Hayashi, Hiromi, Annalisa Ruggeri, Hanadi Rafii - El Ayoubi, et al. "Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT." Blood 128, no. 22 (2016): 3428. http://dx.doi.org/10.1182/blood.v128.22.3428.3428.

Full text

Abstract:

Abstract Chronic Graft-versus-Host Disease (cGVHD) has a negative impact on transplant related death and quality of life after hematopoietic stem cell transplantation. In an attempt to thoroughly assess cGVHD after double umbilical cord blood transplantation (dUCBT), we used the major revised consensus criteria (NCC 2005) proposed by the National Institutes of Health (NIH) in 2005. Material and methods: This is a retrospective study using Eurocord-EBMT database. A specific questionnaire including the NCC 2005 characteristics and features was sent to each transplant centers for collecting data.

APA, Harvard, Vancouver, ISO, and other styles

25

Hanash, Alan M., Lucy W. Kappel, Nury L. Yim, et al. "Abrogation of Donor T Cell IL-21 Signaling Leads to Tissue-Specific Modulation of Immunity and Separation of Gvhd From GVL." Blood 116, no. 21 (2010): 729. http://dx.doi.org/10.1182/blood.v116.21.729.729.

Full text

Abstract:

Abstract Abstract 729 Allogeneic hematopoietic transplantation is frequently the only curative therapy available to patients with hematopoietic malignancies, however transplant success continues to be limited by complications including graft vs. host disease (GVHD) and disease relapse. Separation of GVHD from graft vs. leukemia/lymphoma (GVL) responses continues to be a major goal of experimental and clinical transplantation, and better understanding of T cell immunobiology may lead to novel strategies to accomplish this goal. Interleukin 21 (IL-21) is a pro-inflammatory cytokine produced by T

APA, Harvard, Vancouver, ISO, and other styles

26

Gill, Ronald G., and Leslie Wolf. "Immunobiology of Cellular Transplantation." Cell Transplantation 4, no. 4 (1995): 361–70. http://dx.doi.org/10.1177/096368979500400407.

Full text

Abstract:

The goal of cellular transplantation is to allow long-term function of the grafted cells using minimal host immunosuppression. To this end, the major strategies to implant cells and tissues are through: (i) the pretreatment of the graft to reduce tissue immunogenicity; (ii) the application of immunoisolation technologies to prevent host sensitization to implanted cells; and (iii) the induction of immunological tolerance to the donor tissues. Further, a major dilemma facing clinical tissue grafting is the shortage of donor tissue for transplantation. This problem requires the consideration of t

APA, Harvard, Vancouver, ISO, and other styles

27

Bujía, J., T. Wustrow, and C. Hammer. "Immunobiology of Cartilage Transplants for Functional Nasal Reconstruction." Facial Plastic Surgery 11, no. 03 (1995): 237–43. http://dx.doi.org/10.1055/s-2008-1064538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Vago, Luca, Cristina Toffalori, Müberra Ahci, et al. "Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study." Blood 132, Supplement 1 (2018): 818. http://dx.doi.org/10.1182/blood-2018-99-112142.

Full text

Abstract:

Abstract Introduction. Genomic loss of an HLA haplotype encoding incompatible alleles ("HLA loss") has been described in previous single-center studies as a mechanism by which leukemic cells evade the graft-versus-leukemia effect mediated by alloreactive donor T cells and outgrow into a clinically evident relapse. HLA loss accounts for up to 30% of relapses after HLA-haploidentical transplants (Crucitti, Leukemia 2015), but the actual frequency and clinical relevance of this phenomenon in unrelated donor HSCTs, including cord blood transplants, are largely unknown. Here we present the first gl

APA, Harvard, Vancouver, ISO, and other styles

29

Blount, Jeffrey B., Takeshi Kondoh, Lisa L. Pundt, John Conrad, Elizabeth M. Jansen, and Walter C. Low. "Immunobiology of neural transplants and functional incorporation of grafted dopamine neurons." Behavioral and Brain Sciences 18, no. 1 (1995): 48–49. http://dx.doi.org/10.1017/s0140525x00037286.

Full text

Abstract:

AbstractIn contrast to the views put forth by Stein & Glasier, we support the use of inbred strains of rodents in studies of the immunobiology of neural transplants. Inbred strains demonstrate homology of the major histocompatibility complex (MHC). Virtually all experimental work in transplantation immunology is performed using inbred strains, yet very few published studies of immune rejection in intracerebral grafts have used inbred animals.

APA, Harvard, Vancouver, ISO, and other styles

30

Giannotti, Federica, Annalisa Ruggeri, Myriam Labopin, et al. "Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT." Blood 126, no. 23 (2015): 3111. http://dx.doi.org/10.1182/blood.v126.23.3111.3111.

Full text

Abstract:

Abstract Umbilical cord blood transplantation (UCBT) from unrelated donor is a valid alternative for patients (pts) with acute leukemia (AL) who lack an HLA matched donor. Double UCBT (dUCBT) has extended the use of UCBT to adults. In the majority of the cases, chimerism analysis shows that one unit emerges as the sole source of long term hematopoiesis in the recipient (rcp) following dUCBT. However, no clear factor has yet been identified to reliably predict which unit will emerge as the predominant one. With the aim of analyzing factors that may predict cord blood unit (CBU) predominance and

APA, Harvard, Vancouver, ISO, and other styles

31

Streilein, J. Wayne, Naili Ma, Hartmut Wenkel, Tat Fong Ng, and Parisa Zamiri. "Immunobiology and privilege of neuronal retina and pigment epithelium transplants." Vision Research 42, no. 4 (2002): 487–95. http://dx.doi.org/10.1016/s0042-6989(01)00185-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ruggeri, Annalisa, Carlheinz Mueller, Liesbeth C. de Wreede, et al. "Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)." Blood 134, Supplement_1 (2019): 3281. http://dx.doi.org/10.1182/blood-2019-125369.

Full text

Abstract:

Introduction: Optimal HLA matching is associated with clinical outcome of unrelated donor (UD) hematopoietic cell transplantation (HCT)(Pidala, Blood2014, Morishima, Blood2015, Fürst, Blood2013), but a comprehensive analysis addressing this question in European transplant centers has not yet been performed. Within the CTIWP of EBMT, we have addressed this issue in adultsreceiving an UD-HCT from 2000 to 2015. Methods: All consecutive cases of UC-HCT with available 6-loci high resolution (2nd field) HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 typing for both patient and donor and ARD-level matching for a

APA, Harvard, Vancouver, ISO, and other styles

33

Glyantsev, S. P., and A. Werner. "PHENOMENON OF DEMIKHOV. In the Sklifosovsky Institute (1960–1986). Demichow W. Die experimentelle Transplantation lebenswichtiger Organe. Berlin: VEB Verlag Volk und Gesundheit, 1963." Transplantologiya. The Russian Journal of Transplantation 12, no. 1 (2020): 61–75. http://dx.doi.org/10.23873/2074-0506-2020-12-1-61-75.

Full text

Abstract:

The article has discussed V.P. Demikhov's views on a homoplastic transplantation of tissues and organs in 1963 and his achievements in experimental transplantation by that time. The authors first translated the monograph Die experimentelle Transplantation lebenswichtiger Organe (1963) from German into Russian and presented V.P. Demikhov's Preface to it. In this text, having critically analyzed the current provisions in the field of immunobiology, V.P. Demikhov came to the conclusion that a number of his achievements contradicted those provisions and did not fit into the framework of existing i

APA, Harvard, Vancouver, ISO, and other styles

34

Chiyo, M., T. Iwata, T. J. Webb, et al. "Silencing S1P1 Receptors Regulates Collagen-V Reactive Lymphocyte-Mediated Immunobiology in the Transplanted Lung." American Journal of Transplantation 8, no. 3 (2008): 537–46. http://dx.doi.org/10.1111/j.1600-6143.2007.02116.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Min, Woo-Sung, Heeje Kim, Byoung-Sik Cho, et al. "Comparative 2-Arm Study for Acute Graft-Versus-Host Disease; Antithymocyte Globulin Is More Effective Than Mycofenolate Mofetil on Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation from Mismatched Unrelated Donors." Blood 108, no. 11 (2006): 5395. http://dx.doi.org/10.1182/blood.v108.11.5395.5395.

Full text

Abstract:

Abstract We have experienced many HLA-mismatched unrelated donor hematopoietic stem cell transplantation (HSCT) for patients with high-risk AML. The availability of unrelated donors, who were categorized as high-risk for acute GvHD posttransplant, based on well understanding of impact of HLA allele or antigen mismatch immunobiology on various clinical outcomes, was investigated. With the use of different immunosuppression conditioning regimens, according to the patient-risk grouping, will allow stable HLA-mismatched unrelated donor HSCT to meet the needs best of the individual patient. Beginni

APA, Harvard, Vancouver, ISO, and other styles

36

Aiello, Anna, Giulia Accardi, Giuseppina Candore, et al. "Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing." International Journal of Molecular Sciences 20, no. 3 (2019): 685. http://dx.doi.org/10.3390/ijms20030685.

Full text

Abstract:

The outcome of host-virus interactions is determined by a number of factors, some related to the virus, others to the host, such as environmental factors and genetic factors. Therefore, different individuals vary in their relative susceptibility to infections. Human cytomegalovirus (HCMV) is an important pathogen from a clinical point of view, as it causes significant morbidity and mortality in immunosuppressed or immunosenescent individuals, such as the transplanted patients and the elderly, respectively. It is, therefore, important to understand the mechanisms of virus infection control. In

APA, Harvard, Vancouver, ISO, and other styles

37

Hont, Amy, Conrad Cruz, Maja Stanojevic, et al. "414 Enhancing T cell therapy for patients with relapsed/refractory Wilms tumor." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A439—A440. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0414.

Full text

Abstract:

BackgroundPatients with relapsed or refractory Wilms tumor (WT) have poor prognoses with limited treatment options.1–3 Immunotherapy offers a promising alternative for targeted therapy but has been limited by immune evasion tactics.4–6 Adoptive cell therapy with patient-derived tumor-associated antigen-specific T cells (TAA-T) targeting 3 antigens (WT1, PRAME, and survivin) has the potential to overcome antigen loss. The objective of this phase I clinical trial is to determine the safety of administering TAA-T to patients with high-risk, relapsed/refractory solid tumors. Secondary objectives i

APA, Harvard, Vancouver, ISO, and other styles

38

Hua, X., T. Deuse, J. Velden, et al. "Immunobiology of SCNT Derived Embryonic Stem Cells: Pivotal Role of mtDNA in Rejection of Transplanted Stem Cells." Transplantation Journal 94, no. 10S (2012): 113. http://dx.doi.org/10.1097/00007890-201211271-00208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hua, X., T. Deuse, J. Velden, et al. "Immunobiology of SCNT Derived Embryonic Stem Cells: Pivotal Role of mtDNA in Rejection of Transplanted Stem Cells." Transplantation Journal 94, no. 10S (2012): 463. http://dx.doi.org/10.1097/00007890-201211271-00882.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Battiwalla, Minoo, Kristin Ellis, Steven Z. Pavletic, et al. "HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies." Blood 118, no. 21 (2011): 3094. http://dx.doi.org/10.1182/blood.v118.21.3094.3094.

Full text

Abstract:

Abstract Abstract 3094 The HLA class II DRB1 antigen DR15 is an important immunobiologic marker in immune mediated marrow failure states. DR15 has also been reported in small studies to be associated with favorable outcomes (reduction in acute GVHD and reduced relapse resulting in improved overall survival) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on major transplant outcomes, we conducted a retrospective study of 2, 891 recipients of first marrow or mobilized peripheral blood stem cell transplantation for the treatment of acute myeloid leukemia (n=1038),

APA, Harvard, Vancouver, ISO, and other styles

41

Orazi, Attilio, Robert A. Hromas, Richard S. Neiman, et al. "Posttransplantation Lymphoprolif erative Disorders in Bone Marrow Transplant Recipients Are Aggressive Diseases With a High Incidence of Adverse Histologic and Immunobiologic Features." American Journal of Clinical Pathology 107, no. 4 (1997): 419–29. http://dx.doi.org/10.1093/ajcp/107.4.419.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Rando, T. A., and H. M. Blau. "Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy." Journal of Cell Biology 125, no. 6 (1994): 1275–87. http://dx.doi.org/10.1083/jcb.125.6.1275.

Full text

Abstract:

The transplantation of cultured myoblasts into mature skeletal muscle is the basis for a new therapeutic approach to muscle and non-muscle diseases: myoblast-mediated gene therapy. The success of myoblast transplantation for correction of intrinsic muscle defects depends on the fusion of implanted cells with host myofibers. Previous studies in mice have been problematic because they have involved transplantation of established myogenic cell lines or primary muscle cultures. Both of these cell populations have disadvantages: myogenic cell lines are tumorigenic, and primary cultures contain a su

APA, Harvard, Vancouver, ISO, and other styles

43

Rocha, Vanderson, Federica Giannotti, Annalisa Ruggeri, et al. "Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study." Blood 126, no. 23 (2015): 3214. http://dx.doi.org/10.1182/blood.v126.23.3214.3214.

Full text

Abstract:

Abstract Despite the increased inventory of "rich" and more diverse HLA cord blood units (CBUs), most adults are still transplanted with double unrelated CBUs. Many studies have described criteria for CBU selection for single UCBT (SUCBT) based on cell dose, low and high resolution (LR and HR) HLA typing, KIR and NIMA. However, the criteria based on these factors for selecting double CBUs are still not as well defined. Moreover, most of SUCBT are performed in children whereas double UCBT (DUCBT) are commonly used for adults, therefore CBUs selection criteria may be different between in these t

APA, Harvard, Vancouver, ISO, and other styles

44

Waskow, Claudia, Susann Rahmig, and Nehir Cosgun. "Kit Deficiency Regulates Stable Human Hematopoietic Stem Cell Engraftment in Mice." Blood 124, no. 21 (2014): 653. http://dx.doi.org/10.1182/blood.v124.21.653.653.

Full text

Abstract:

Abstract Humanized mice are required for in-depth analysis of human hematopoietic stem cell (HSC) function and immunobiology. The currently available options are problematic because stable engraftment of substantial numbers of human HSCs and the continuous generation of human myeloid cell types remain difficult to achieve. We generated three novel recipient mouse strains that combine immune deficiency with a functionally impaired endogenous HSC compartment mediated by a defective Kit receptor: BALB/c Rag2- Il2rg-KitWv/Wv (BRgWv), NOD/SCID Il2rg- (NSG) KitWv/Wv (NSGWv) and NSG KitW41/W41 (NSGW4

APA, Harvard, Vancouver, ISO, and other styles

45

Baron, Frederic, Ruggeri Annalisa, Eric Beohou, et al. "Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation." Blood 126, no. 23 (2015): 155. http://dx.doi.org/10.1182/blood.v126.23.155.155.

Full text

Abstract:

Abstract BACKRGOUND. Non-relapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditionings (RIC) for UCBT have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. The aim of our retrospective registry study was to compare outcomes of acute leukemia (AL) adult patients given UCBT after either RIC or MAC regimens. Regimens were classified as MAC or RIC based on EBMT criteria.

APA, Harvard, Vancouver, ISO, and other styles

46

Toffalori, Cristina, Michela Riba, Laura Zito, et al. "Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation." Blood 124, no. 21 (2014): 427. http://dx.doi.org/10.1182/blood.v124.21.427.427.

Full text

Abstract:

Abstract INTRODUCTION: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) represents an effective form of adoptive immunotherapy for Acute Myeloid Leukemia (AML), thanks to the antitumor effect mediated by donor immune cells infused as part of the graft. Unfortunately, post-transplantation relapses remain a frequent observation, warranting further investigation on AML immunobiology. Our group demonstrated that relapses after partially HLA-incompatible HSCT are frequently due to the outgrowth of immune-resistant mutant AML clones characterized by genomic loss the mismatched histocom

APA, Harvard, Vancouver, ISO, and other styles

47

Du Rocher, Barbara, Odette M. Smith, Andrew M. Intlekofer, et al. "Eomesodermin Regulates The Early Activation Of Alloreactive CD4 T Cells and Is Critical For Both Gvh and GVL Responses." Blood 122, no. 21 (2013): 133. http://dx.doi.org/10.1182/blood.v122.21.133.133.

Full text

Abstract:

Abstract Despite increasing insights into its immunobiology, graft vs host disease (GVHD) remains a major obstacle for successful allogeneic hematopoietic stem/progenitor cell transplantation (allo-HCT). Separation of GVHD from graft vs. leukemia/lymphoma (GVL) responses also remains an elusive goal for allo-HSCT. Efforts to delineate the transcriptional networks regulating T cell differentiation post-HCT have suggested that multiple transcription factors may be involved in the regulation of alloreactive helper T (Th) cells and GVHD. However, conflicting data have emerged regarding the role of

APA, Harvard, Vancouver, ISO, and other styles

48

KK, Miller. "Transplant and Stem Cell Immunobiology: Translational Directions for Cardiovascular Disease Research." Transplantation Research Journal 1, no. 1 (2016). http://dx.doi.org/10.16966/2473-1730.e101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Poster Session 1: Cellular Immunobiology, Preservation, and Cell Transplantation in Transplant; Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma." Hepatology 62 (October 2015): 380A—456A. http://dx.doi.org/10.1002/hep.28212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Habal, Marlena V. "Current Desensitization Strategies in Heart Transplantation." Frontiers in Immunology 12 (August 24, 2021). http://dx.doi.org/10.3389/fimmu.2021.702186.

Full text

Abstract:

Heart transplant candidates sensitized to HLA antigens wait longer for transplant, are at increased risk of dying while waiting, and may not be listed at all. The increasing prevalence of HLA sensitization and limitations of current desensitization strategies underscore the urgent need for a more effective approach. In addition to pregnancy, prior transplant, and transfusions, patients with end-stage heart failure are burdened with unique factors placing them at risk for HLA sensitization. These include homograft material used for congenital heart disease repair and left ventricular assist dev

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!